- Home
- BSTZ vs SNDX Comparison
BSTZ vs SNDX Comparison
Compare BSTZ & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSTZ
- SNDX
- Stock Information
- Founded
- BSTZ 2019
- SNDX 2005
- Country
- BSTZ United States
- SNDX United States
- Employees
- BSTZ N/A
- SNDX N/A
- Industry
- BSTZ Trusts Except Educational Religious and Charitable
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BSTZ Finance
- SNDX Health Care
- Exchange
- BSTZ Nasdaq
- SNDX Nasdaq
- Market Cap
- BSTZ 1.5B
- SNDX 1.4B
- IPO Year
- BSTZ N/A
- SNDX 2016
- Fundamental
- Price
- BSTZ $20.67
- SNDX $13.08
- Analyst Decision
- BSTZ
- SNDX Strong Buy
- Analyst Count
- BSTZ 0
- SNDX 11
- Target Price
- BSTZ N/A
- SNDX $37.64
- AVG Volume (30 Days)
- BSTZ 303.2K
- SNDX 2.2M
- Earning Date
- BSTZ 01-01-0001
- SNDX 11-05-2024
- Dividend Yield
- BSTZ 8.31%
- SNDX N/A
- EPS Growth
- BSTZ N/A
- SNDX N/A
- EPS
- BSTZ 0.71
- SNDX N/A
- Revenue
- BSTZ N/A
- SNDX $16,000,000.00
- Revenue This Year
- BSTZ N/A
- SNDX N/A
- Revenue Next Year
- BSTZ N/A
- SNDX N/A
- P/E Ratio
- BSTZ $26.69
- SNDX N/A
- Revenue Growth
- BSTZ N/A
- SNDX N/A
- 52 Week Low
- BSTZ $14.11
- SNDX $12.76
- 52 Week High
- BSTZ $19.43
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- BSTZ 34.41
- SNDX 28.91
- Support Level
- BSTZ $21.65
- SNDX $13.26
- Resistance Level
- BSTZ $22.08
- SNDX $14.18
- Average True Range (ATR)
- BSTZ 0.33
- SNDX 0.83
- MACD
- BSTZ -0.19
- SNDX -0.18
- Stochastic Oscillator
- BSTZ 0.47
- SNDX 7.08
About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.